The effect of vitamin D on fibroblast growth factor 23: a systematic review and meta-analysis of randomized controlled trials
Open Access
- 26 August 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in European Journal of Clinical Nutrition
- Vol. 75 (6), 980-987
- https://doi.org/10.1038/s41430-020-00725-0
Abstract
The phosphaturic hormone fibroblast growth factor 23 (FGF23) is a risk marker of cardiovascular and all-cause mortality. We therefore aimed to synthesize the evidence for the effect of vitamin D administration on circulating FGF23 concentrations. We performed a systematic review and meta-analysis of randomized, placebo-controlled trials (RCTs) in several databases from inception to January 2020. A total of 73 records were identified for full-text review, and 21 articles with 23 studies were included in the final analysis. The selected studies included 1925 participants with 8-156 weeks of follow-up. The weighted mean difference in FGF23 in the vitamin D versus placebo group was +21 pg/ml (95% CI: 13-28 pg/ml;P < 0.001) with considerable heterogeneity among studies (I-2 = 99%). The FGF23 increment was higher in patients with end-stage kidney/heart failure than in other individuals (+300 pg/ml [95% CI: 41-558 pg/ml] vs. +20 pg/ml [95% CI: 12-28 pg/ml],P-interaction = 0.03), and if baseline 25-hydroxyvitamin D concentrations were = 50 nmol/l (+34 pg/ml [95% CI: 18-51 pg/ml] vs. +9 pg/ml [95% CI: 3-14 pg/ml];P-interaction = 0.002). Moreover, the FGF23 increment was influenced by vitamin D dose/type (vitamin D dose equivalent <= 2000 IU/day: +2 pg/ml [95% CI: 0-3 pg/ml]; vitamin D dose equivalent > 2000 IU/day: +18 pg/ml [95% CI: 6-30 pg/ml]; administration of activated vitamin D: +67 pg/ml [95% CI: 16-117 pg/ml];P-interaction = 0.001). Results were not significantly influenced by study duration (P-interaction = 0.14), age class (P-interaction = 0.09), or assay provider (P-interaction = 0.11). In conclusion, this meta-analysis of RCTs demonstrates that vitamin D administration of >2000 IU/d vitamin D or activated vitamin D significantly increased concentrations of the cardiovascular risk marker FGF23, especially in patients with end-stage kidney/heart failure.This publication has 33 references indexed in Scilit:
- Effect of calcium phosphate and vitamin D3supplementation on bone remodelling and metabolism of calcium, phosphorus, magnesium and ironNutrition Journal, 2014
- Influence of Cholecalciferol Supplementation in Hemodialysis Patients on Monocyte Subsets: A Randomized, Double-Blind, Placebo-Controlled Clinical TrialNephron Clinical Practice, 2013
- Phosphate Toxicity and Vascular MineralizationContributions to nephrology, 2013
- FGF23 induces left ventricular hypertrophyJCI Insight, 2011
- Evaluation of a Method for Fibroblast Growth Factor-23: A Novel Biomarker of Adverse Outcomes in Patients with Renal DiseaseMetabolic Syndrome and Related Disorders, 2010
- A Bimodal Association of Vitamin D Levels and Vascular Disease in Children on DialysisJournal of the American Society of Nephrology, 2008
- Vitamin D DeficiencyThe New England Journal of Medicine, 2007
- Differential effects of 19-nor-1,25-(OH)2D2 and 1α-hydroxyvitamin D2 on calcium and phosphorus in normal and uremic ratsKidney International, 2002
- Quantifying heterogeneity in a meta-analysisStatistics in Medicine, 2002
- A comparison of methods to detect publication bias in meta‐analysisStatistics in Medicine, 2001